Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk
Key Takeaways:
BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law
The change could reduce the company’s threat of being forcibly delisted from the Nasdaq
By Doug Young
Benzinga ·